Klarquist Sparkman to speak at 4th Protein Discovery & Therapeutics Meeting Oct 19-21 in San Diego

MONROVIA, CA, August 12, 2011 (Press-News.org) Susan Alpert Siegel Ph.D. and William D. Noonan M.D. of Klarquist Sparkman to give a featured presentation entitled "Patenting Protein Therapeutics: In the Shadow of Uncertainty" at GTC's 4th Protein Discovery & Therapeutics Conference on Oct 19-21, 2011 in San Diego, CA

Dr's Siegel and Noonan will discuss how therapeutic proteins are patented in a purified, synthetic or artificial form to distinguish them from unpatentable products of nature. Patentable proteins must also be new, useful and nonobvious. As patents expire on antibodies, patent strategies are needed to try to delay generic competition and extend the product lifecycle, such as by patenting affinity matured antibodies, pharmaceutical formulations, antibody conjugates and new therapeutic methods.

Dr. Siegel is a senior member of the Life Sciences Group at Klarquist Sparkman LLP. She has prepared and prosecuted U.S., international and foreign patent applications for corporate clients, universities and non-profit institutions for over 13 years. Dr. Siegel's practice emphasis is in biotechnology including applications relating to therapeutic proteins, immunogens, antibodies, vaccines, methods of treatment, diagnostics, pharmaceuticals and medical devices. She specializes in obtaining patents relating to antibodies and their use.

Dr. Noonan is the chair of the Life Sciences Group at Klarquist Sparkman LLP. He prepares and prosecutes U.S. and foreign patent applications. He works on technologies related to immunology, molecular biology, biochemistry, pharmacology, medical and surgical devices, engineered proteins, vaccines, and imaging analysis. As a physician and a patent attorney, Dr. Noonan provides clients with a broad perspective about the practical applications of medical and biological inventions.

Other topics to be discussed at the conference include bi-specific and multi-specific fusion proteins, modified proteins, antibody drug conjugates, biosimilars and biosuperiors, non-IG scaffolds, antibody fragments, new peptide approaches, nutraceuticals, advances in expression systems, immunogenicity, aggregation, subvisible particles, stability and delivery of proteins.

Also presenting at the 4th Protein Discovery & Therapeutics Conference are organizations active in the field including Affibody, Affimed, Albany Medical College, Ambrx, Anaptysbio, Centyrex, ImmunGene, Johnson & Johnson, MacroGenics, MedImmune, Merus, Micromet AG, NCI, NIH, Nektar Therapeutics, Novartis, NovImmune SA, Pfizer, Profectus BioSciences, RC Technologies, Roche, Scripps Research Institute, Zyngenia and other experts in protein therapeutics. For more information, please visit http://www.gtcbio.com.

ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com